Mucins and tumor resistance to chemotherapeutic drugs

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1846, Issue 1, 2014, Pages 142-151

  Jonckheere, Nicolas ^a,b,c   Skrypek, Nicolas ^a,b,c   Van Seuningen, Isabelle ^a,b,c  

^a JEAN PIERRE AUBERT RESEARCH CENTER   (France)

^b UNIV LILLE   (France)

^c LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

Apoptosis; Cancer; Chemotherapeutic drug; Mucin; Prognosis biomarker; Resistance

Indexed keywords

ANTINEOPLASTIC AGENT; BORTEZOMIB; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEOXYGLUCOSE; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; GEMCITABINE; LAPATINIB; METHOTREXATE; MUCIN; MUCIN 1; MUCIN 2; MUCIN 3; MUCIN 4; MUCIN 5AC; MUCIN 5B; PACLITAXEL; PLATINUM DERIVATIVE; RHODAMINE 123; TAMOXIFEN; TAXANE DERIVATIVE; TRASTUZUMAB; VINBLASTINE;

APOPTOSIS; BREAST CANCER; CANCER STEM CELL; COLORECTAL CANCER; COLORECTAL CARCINOMA; DRUG MECHANISM; DRUG METABOLISM; ENDOMETRIUM CARCINOMA; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; IN VITRO STUDY; KIDNEY CARCINOMA; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; MUC1 GENE; MUC4 GENE; NONHUMAN; ONCOGENE; OVARY CANCER; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN FUNCTION; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; STOMACH CANCER; TUMOR RESISTANCE; UTERUS CARCINOMA;

APOPTOSIS; CANCER; CHEMOTHERAPEUTIC DRUG; MUCIN; PROGNOSIS BIOMARKER; RESISTANCE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; DRUG RESISTANCE, NEOPLASM; EPITHELIAL-MESENCHYMAL TRANSITION; HUMANS; METABOLIC DETOXICATION, DRUG; MUCINS; NEOPLASMS; POLYMORPHISM, GENETIC;

EID: 84901413878     PISSN: 0304419X     EISSN: 18792561     Source Type: Journal    
DOI: 10.1016/j.bbcan.2014.04.008     Document Type: Review

References (143)

1. Roussel P., Lamblin G., Lhermitte M., Houdret N., Lafitte J.J., Perini J.M., Klein A., Scharfman A. The complexity of mucins. Biochimie 1988, 70:1471-1482.
2. Dekker J., Rossen J.W., Buller H.A., Einerhand A.W. The MUC family: an obituary. Trends Biochem. Sci. 2002, 27:126-131.
3. Gendler S.J., Spicer A.P. Epithelial mucin genes. Annu. Rev. Physiol. 1995, 57:607-634.
4. Thornton D.J., Rousseau K., McGuckin M.A. Structure and function of the polymeric mucins in airways mucus. Annu. Rev. Physiol. 2008, 70:459-486.
5. Desseyn J.L., Gouyer V., Tetaert D. Architecture of the gel-forming mucins. The Epithelial Mucins: Structure/Function. Roles in Cancer and Inflammatory Diseases 2008, 1-16. Research Signpost, Kerala, India. I. Van Seuningen (Ed.).
6. Baldus S.E., Engelmann K., Hanisch F.G. MUC1 and the MUCs: a family of human mucins with impact in cancer biology. Crit. Rev. Clin. Lab. Sci. 2004, 41:189-231.
7. Tran D.T., Ten Hagen K.G. Mucin-type O-glycosylation during development. J. Biol. Chem. 2013, 288:6921-6929.
8. Groux-Degroote S., Harduin-Lepers A., Delannoy P. Biosynthesis of mucin O-glycan chains in normal and pathological states. The Epithelial Mucins: Structure/Function. Roles in Cancer and Inflammatory Diseases 2008, 39-54. Research Signpost, Kerala, India. I. Van Seuningen (Ed.).
9. Desseyn J.L. Mucin CYS domains are ancient and highly conserved modules that evolved in concert. Mol. Phylogenet. Evol. 2009, 52:284-292.
10. Ambort D., Johansson M.E., Gustafsson J.K., Ermund A., Hansson G.C. Perspectives on mucus properties and formation-lessons from the biochemical world. Cold Spring Harb. Perspect. Med. 2012, 2. (pii: a014159).
11. Backstrom M., Ambort D., Thomsson E., Johansson M.E., Hansson G.C. Increased understanding of the biochemistry and biosynthesis of MUC2 and other gel-forming mucins through the recombinant expression of their protein domains. Mol. Biotechnol. 2013, 54:250-256.
12. Hattrup C.L., Gendler S.J. Structure and function of the cell surface (tethered) mucins. Annu. Rev. Physiol. 2008, 70:431-457.
13. Jonckheere N., Skrypek N., Frenois F., Van Seuningen I. Membrane-bound mucin modular domains: from structure to function. Biochimie 2013, 95:1077-1086.
14. Jonckheere N., Van Seuningen I. The membrane-bound mucins: how large O-glycoproteins play key roles in epithelial cancers and hold promise as biological tools for gene-based and immunotherapies. Crit. Rev. Oncog. 2008, 14:177-196.
15. Desseyn J.L., Tetaert D., Gouyer V. Architecture of the large membrane-bound mucins. Gene 2008, 410:215-222.
16. Perez B.H., Gipson I.K. Focus on molecules: human mucin MUC16. Exp. Eye Res. 2008, 87:400-401.
17. Jonckheere N., Van Seuningen I. The membrane-bound mucins: from cell signalling to transcriptional regulation and expression in epithelial cancers. Biochimie 2010, 92:1-11.
18. Van Seuningen I., Pigny P., Perrais M., Porchet N., Aubert J.P. Transcriptional regulation of the 11p15 mucin genes. Towards new biological tools in human therapy, in inflammatory diseases and cancer?. Front. Biosci. 2001, 6:D1216-D1234.
19. Pinto R., Carvalho A.S., Conze T., Magalhaes A., Picco G., Burchell J.M., Taylor-Papadimitriou J., Reis C.A., Almeida R., Mandel U., Clausen H., Soderberg O., David L. Identification of new cancer biomarkers based on aberrant mucin glycoforms by in situ proximity ligation. J. Cell. Mol. Med. 2012, 16:1474-1484.
20. Robbe-Masselot C., Michalski J.C., Capon C. Tumour-associated antigens of mucin O-glycans. Clinical relevance of glycobiology in cancer and inflammatory diseases of the epithelium. The Epithelial Mucins: Structure/Function. Roles in Cancer and Inflammatory Diseases 2008, 55-74. Research Signpost, Kerala, India. I. Van Seuningen (Ed.).
21. Argueso P., Gipson I.K. Assessing mucin expression and function in human ocular surface epithelia in vivo and in vitro. Methods Mol. Biol. 2012, 842:313-325.
22. Hollingsworth M.A., Swanson B.J. Mucins in cancer: protection and control of the cell surface. Nat. Rev. Cancer 2004, 4:45-60.
23. Jonckheere N., Skrypek N., van Seuningen I. Mucins and pancreatic cancer. Cancers 2010, 2:1794-1812.
24. Kaur S., Kumar S., Momi N., Sasson A.R., Batra S.K. Mucins in pancreatic cancer and its microenvironment. Nat. Rev. Gastroenterol. Hepatol. 2013, 10:607-620.
25. Kufe D.W. Mucins in cancer: function, prognosis and therapy. Nat. Rev. Cancer 2009, 9:874-885.
26. Hoshi H., Sawada T., Uchida M., Saito H., Iijima H., Toda-Agetsuma M., Wada T., Yamazoe S., Tanaka H., Kimura K., Kakehashi A., Wei M., Hirakawa K., Wanibuchi H. Tumor-associated MUC5AC stimulates in vivo tumorigenicity of human pancreatic cancer. Int. J. Oncol. 2011, 38:619-627.
27. Valque H., Gouyer V., Gottrand F., Desseyn J.L. MUC5B leads to aggressive behavior of breast cancer MCF7 cells. PLoS ONE 2012, 7:e46699.
28. Yamazoe S., Tanaka H., Sawada T., Amano R., Yamada N., Ohira M., Hirakawa K. RNA interference suppression of mucin 5AC (MUC5AC) reduces the adhesive and invasive capacity of human pancreatic cancer cells. J. Exp. Clin. Cancer Res. 2010, 29:53.
29. Chauhan S.C., Ebeling M.C., Maher D.M., Koch M.D., Watanabe A., Aburatani H., Lio Y., Jaggi M. MUC13 mucin augments pancreatic tumorigenesis. Mol. Cancer Ther. 2012, 11:24-33.
30. Maher D.M., Gupta B.K., Nagata S., Jaggi M., Chauhan S.C. Mucin 13: structure, function, and potential roles in cancer pathogenesis. Mol. Cancer Res. 2011, 9:531-537.
31. Lakshmanan I., Ponnusamy M.P., Das S., Chakraborty S., Haridas D., Mukhopadhyay P., Lele S.M., Batra S.K. MUC16 induced rapid G2/M transition via interactions with JAK2 for increased proliferation and anti-apoptosis in breast cancer cells. Oncogene 2012, 31:805-817.
32. Velcich A., Yang W., Heyer J., Fragale A., Nicholas C., Viani S., Kucherlapati R., Lipkin M., Yang K., Augenlicht L. Colorectal cancer in mice genetically deficient in the mucin Muc2. Science 2002, 295:1726-1729.
33. Dahiya R., Lesuffleur T., Kwak K.S., Byrd J.C., Barbat A., Zweibaum A., Kim Y.S. Expression and characterization of mucins associated with the resistance to methotrexate of human colonic adenocarcinoma cell line HT29. Cancer Res. 1992, 52:4655-4662.
34. Lesuffleur T., Porchet N., Aubert J.P., Swallow D., Gum J.R., Kim Y.S., Real F.X., Zweibaum A. Differential expression of the human mucin genes MUC1 to MUC5 in relation to growth and differentiation of different mucus-secreting HT-29 cell subpopulations. J. Cell Sci. 1993, 106(Pt 3):771-783.
35. Leteurtre E., Gouyer V., Rousseau K., Moreau O., Barbat A., Swallow D., Huet G., Lesuffleur T. Differential mucin expression in colon carcinoma HT-29 clones with variable resistance to 5-fluorouracil and methotrexate. Biol. Cell. 2004, 96:145-151.
36. Fessler S.P., Wotkowicz M.T., Mahanta S.K., Bamdad C. MUC1* is a determinant of trastuzumab (Herceptin) resistance in breast cancer cells. Breast Cancer Res. Treat. 2009, 118:113-124.
37. Deng M., Jing D.D., Meng X.J. Effect of MUC1 siRNA on drug resistance of gastric cancer cells to trastuzumab. Asian Pac. J. Cancer Prev. 2013, 14:127-131.
38. Shi M., Yang Z., Hu M., Liu D., Hu Y., Qian L., Zhang W., Chen H., Guo L., Yu M., Song L., Ma Y., Guo N. Catecholamine-Induced beta2-adrenergic receptor activation mediates desensitization of gastric cancer cells to trastuzumab by upregulating MUC4 expression. J. Immunol. 2013, 190:5600-5608.
39. Chen A.C., Migliaccio I., Rimawi M., Lopez-Tarruella S., Creighton C.J., Massarweh S., Huang C., Wang Y.C., Batra S.K., Gutierrez M.C., Osborne C.K., Schiff R. Upregulation of mucin4 in ER-positive/HER2-overexpressing breast cancer xenografts with acquired resistance to endocrine and HER2-targeted therapies. Breast Cancer Res. Treat. 2012, 134:583-593.
40. Bafna S., Kaur S., Momi N., Batra S.K. Pancreatic cancer cells resistance to gemcitabine: the role of MUC4 mucin. Br. J. Cancer 2009, 101:1155-1161.
41. Mimeault M., Johansson S.L., Senapati S., Momi N., Chakraborty S., Batra S.K. MUC4 down-regulation reverses chemoresistance of pancreatic cancer stem/progenitor cells and their progenies. Cancer Lett. 2010, 295:69-84.
42. Skrypek N., Duchene B., Hebbar M., Leteurtre E., van Seuningen I., Jonckheere N. The MUC4 mucin mediates gemcitabine resistance of human pancreatic cancer cells via the Concentrative Nucleoside Transporter family. Oncogene 2013, 32:1714-1723.
43. Wissniowski T.T., Meister S., Hahn E.G., Kalden J.R., Voll R., Ocker M. Mucin production determines sensitivity to bortezomib and gemcitabine in pancreatic cancer cells. Int. J. Oncol. 2012, 40:1581-1589.
44. Hu Y.P., Haq B., Carraway K.L., Savaraj N., Lampidis T.J. Multidrug resistance correlates with overexpression of Muc4 but inversely with P-glycoprotein and multidrug resistance related protein in transfected human melanoma cells. Biochem. Pharmacol. 2003, 65:1419-1425.
45. Mekenkamp L.J., Heesterbeek K.J., Koopman M., Tol J., Teerenstra S., Venderbosch S., Punt C.J., Nagtegaal I.D. Mucinous adenocarcinomas: poor prognosis in metastatic colorectal cancer. Eur. J. Cancer 2012, 48:501-509.
46. Nagao T., Kinoshita T., Hojo T., Tsuda H., Tamura K., Fujiwara Y. The differences in the histological types of breast cancer and the response to neoadjuvant chemotherapy: the relationship between the outcome and the clinicopathological characteristics. Breast 2012, 21:289-295.
47. Oberholzer K., Menig M., Kreft A., Schneider A., Junginger T., Heintz A., Kreitner K.F., Hotker A.M., Hansen T., Duber C., Schmidberger H. Rectal cancer: mucinous carcinoma on magnetic resonance imaging indicates poor response to neoadjuvant chemoradiation. Int. J. Radiat. Oncol. Biol. Phys. 2012, 82:842-848.
48. Poujade O., Morice P., Rouzier R., Madelenat P., Lecuru F., Muray J.M., Mathevet P., Alran S., Salmon R.J., Reyal F. Pathologic response rate after concomitant neo-adjuvant radiotherapy and chemotherapy for adenocarcinoma of the uterine cervix: a retrospective multicentric study. Int. J. Gynecol. Cancer 2010, 20:815-820.
49. Messager M., Lefevre J.H., Pichot-Delahaye V., Souadka A., Piessen G., Mariette C. The impact of perioperative chemotherapy on survival in patients with gastric signet ring cell adenocarcinoma: a multicenter comparative study. Ann. Surg. 2011, 254:684-693. (discussion 693).
50. Sinn B.V., von Minckwitz G., Denkert C., Eidtmann H., Darb-Esfahani S., Tesch H., Kronenwett R., Hoffmann G., Belau A., Thommsen C., Holzhausen H.J., Grasshoff S.T., Baumann K., Mehta K., Dietel M., Loibl S. Evaluation of Mucin-1 protein and mRNA expression as prognostic and predictive markers after neoadjuvant chemotherapy for breast cancer. Ann. Oncol. 2013, 24:2316-2324.
51. Pitroda S.P., Khodarev N.N., Beckett M.A., Kufe D.W., Weichselbaum R.R. MUC1-induced alterations in a lipid metabolic gene network predict response of human breast cancers to tamoxifen treatment. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:5837-5841.
52. Takano M., Fujii K., Kita T., Kikuchi Y., Uchida K. Amplicon profiling reveals cytoplasmic overexpression of MUC1 protein as an indicator of resistance to platinum-based chemotherapy in patients with ovarian cancer. Oncol. Rep. 2004, 12:1177-1182.
53. Zhang D., Gao J., Zhu L., Hu Z., Hou R., Liu S., Tan M., Liu J., Lin B. Chemoresistance is associated with MUC1 and Lewis y antigen expression in ovarian epithelial cancers. Int. J. Mol. Sci. 2013, 14:11024-11033.
54. Bhat P.G., Flanagan D.R., Donovan M.D. Drug diffusion through cystic fibrotic mucus: steady-state permeation, rheologic properties, and glycoprotein morphology. J. Pharm. Sci. 1996, 85:624-630.
55. Shaw L.R., Irwin W.J., Grattan T.J., Conway B.R. The influence of excipients on the diffusion of ibuprofen and paracetamol in gastric mucus. Int. J. Pharm. 2005, 290:145-154.
56. Sigurdsson H.H., Kirch J., Lehr C.M. Mucus as a barrier to lipophilic drugs. Int. J. Pharm. 2013, 453:56-64.
57. Khanvilkar K., Donovan M.D., Flanagan D.R. Drug transfer through mucus. Adv. Drug Deliv. Rev. 2001, 48:173-193.
58. Kalra A.V., Campbell R.B. Mucin impedes cytotoxic effect of 5-FU against growth of human pancreatic cancer cells: overcoming cellular barriers for therapeutic gain. Br. J. Cancer 2007, 97:910-918.
59. Leteurtre E., Gouyer V., Delacour D., Hemon B., Pons A., Richet C., Zanetta J.P., Huet G. Induction of a storage phenotype and abnormal intracellular localization of apical glycoproteins are two independent responses to GalNAcalpha-O-bn. J. Histochem. Cytochem. 2003, 51:349-361.
60. Kalra A.V., Campbell R.B. Mucin overexpression limits the effectiveness of 5-FU by reducing intracellular drug uptake and antineoplastic drug effects in pancreatic tumours. Eur. J. Cancer 2009, 45:164-173.
61. Lafitte G., Thuresson K., Soderman O. Diffusion of nutrients molecules and model drug carriers through mucin layer investigated by magnetic resonance imaging with chemical shift resolution. J. Pharm. Sci. 2007, 96:258-263.
62. Gubbels J.A., Felder M., Horibata S., Belisle J.A., Kapur A., Holden H., Petrie S., Migneault M., Rancourt C., Connor J.P., Patankar M.S. MUC16 provides immune protection by inhibiting synapse formation between NK and ovarian tumor cells. Mol. Cancer 2010, 9:11.
63. Komatsu M., Yee L., Carraway K.L. Overexpression of sialomucin complex, a rat homologue of MUC4, inhibits tumor killing by lymphokine-activated killer cells. Cancer Res. 1999, 59:2229-2236.
64. van de Wiel-van Kemenade E., Ligtenberg M.J., de Boer A.J., Buijs F., Vos H.L., Melief C.J., Hilkens J., Figdor C.G. Episialin (MUC1) inhibits cytotoxic lymphocyte-target cell interaction. J. Immunol. 1993, 151:767-776.
65. Price-Schiavi S.A., Jepson S., Li P., Arango M., Rudland P.S., Yee L., Carraway K.L. Rat Muc4 (sialomucin complex) reduces binding of anti-ErbB2 antibodies to tumor cell surfaces, a potential mechanism for herceptin resistance. Int. J. Cancer 2002, 99:783-791.
66. Nagy P., Friedlander E., Tanner M., Kapanen A.I., Carraway K.L., Isola J., Jovin T.M. Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptin-resistant, MUC4-expressing breast cancer cell line. Cancer Res. 2005, 65:473-482.
67. Ren J., Agata N., Chen D., Li Y., Yu W.H., Huang L., Raina D., Chen W., Kharbanda S., Kufe D. Human MUC1 carcinoma-associated protein confers resistance to genotoxic anticancer agents. Cancer Cell 2004, 5:163-175.
68. Wei X., Xu H., Kufe D. Human MUC1 oncoprotein regulates p53-responsive gene transcription in the genotoxic stress response. Cancer Cell 2005, 7:167-178.
69. Ahmad R., Alam M., Rajabi H., Kufe D. The MUC1-C oncoprotein binds to the BH3 domain of the pro-apoptotic BAX protein and blocks BAX function. J. Biol. Chem. 2012, 287:20866-20875.
70. Raina D., Ahmad R., Kumar S., Ren J., Yoshida K., Kharbanda S., Kufe D. MUC1 oncoprotein blocks nuclear targeting of c-Abl in the apoptotic response to DNA damage. EMBO J. 2006, 25:3774-3783.
71. Raina D., Ahmad R., Chen D., Kumar S., Kharbanda S., Kufe D. MUC1 oncoprotein suppresses activation of the ARF-MDM2-p53 pathway. Cancer Biol. Ther. 2008, 7:1959-1967.
72. Ahmad R., Raina D., Trivedi V., Ren J., Rajabi H., Kharbanda S., Kufe D. MUC1 oncoprotein activates the IkappaB kinase beta complex and constitutive NF-kappaB signalling. Nat. Cell Biol. 2007, 9:1419-1427.
73. Agata N., Ahmad R., Kawano T., Raina D., Kharbanda S., Kufe D. MUC1 oncoprotein blocks death receptor-mediated apoptosis by inhibiting recruitment of caspase-8. Cancer Res. 2008, 68:6136-6144.
74. Bouillez A., Gnemmi V., Gaudelot K., Hemon B., Ringot B., Pottier N., Glowacki F., Butruille C., Cauffiez C., Hamdane M., Sergeant N., Van Seuningen I., Leroy X., Aubert S., Perrais M. MUC1-C nuclear localization drives invasiveness of renal cancer cells through a sheddase/gamma secretase dependent pathway. Oncotarget 2014, 5:754-763.
75. Lau A.T., Wang Y., Chiu J.F. Reactive oxygen species: current knowledge and applications in cancer research and therapeutic. J. Cell. Biochem. 2008, 104:657-667.
76. Storz P. Reactive oxygen species in tumor progression. Front. Biosci. 2005, 10:1881-1896.
77. Yin L., Li Y., Ren J., Kuwahara H., Kufe D. Human MUC1 carcinoma antigen regulates intracellular oxidant levels and the apoptotic response to oxidative stress. J. Biol. Chem. 2003, 278:35458-35464.
78. Yin L., Huang L., Kufe D. MUC1 oncoprotein activates the FOXO3a transcription factor in a survival response to oxidative stress. J. Biol. Chem. 2004, 279:45721-45727.
79. Fruehauf J.P., Meyskens F.L. Reactive oxygen species: a breath of life or death?. Clin. Cancer Res. 2007, 13:789-794.
80. Aubert S., Fauquette V., Hemon B., Lepoivre R., Briez N., Bernard D., Van Seuningen I., Leroy X., Perrais M. MUC1, a new hypoxia inducible factor target gene, is an actor in clear renal cell carcinoma tumor progression. Cancer Res. 2009, 69:5707-5715.
81. Chaturvedi P., Singh A.P., Moniaux N., Senapati S., Chakraborty S., Meza J.L., Batra S.K. MUC4 mucin potentiates pancreatic tumor cell proliferation, survival, and invasive properties and interferes with its interaction to extracellular matrix proteins. Mol. Cancer Res. 2007, 5:309-320.
82. Moniaux N., Chaturvedi P., Varshney G.C., Meza J.L., Rodriguez-Sierra J.F., Aubert J.P., Batra S.K. Human MUC4 mucin induces ultra-structural changes and tumorigenicity in pancreatic cancer cells. Br. J. Cancer 2007, 97:345-357.
83. Torres M.P., Ponnusamy M.P., Chakraborty S., Smith L.M., Das S., Arafat H.A., Batra S.K. Effects of thymoquinone in the expression of mucin 4 in pancreatic cancer cells: implications for the development of novel cancer therapies. Mol. Cancer Ther. 2010, 9:1419-1431.
84. Jonckheere N., Skrypek N., Merlin J., Dessein A.F., Dumont P., Leteurtre E., Harris A., Desseyn J.L., Susini C., Frenois F., Van Seuningen I. The mucin MUC4 and its membrane partner ErbB2 regulate biological properties of human CAPAN-2 pancreatic cancer cells via different signalling pathways. PLoS ONE 2012, 7:e32232.
85. Komatsu M., Jepson S., Arango M.E., Carothers Carraway C.A., Carraway K.L. Muc4/sialomucin complex, an intramembrane modulator of ErbB2/HER2/Neu, potentiates primary tumor growth and suppresses apoptosis in a xenotransplanted tumor. Oncogene 2001, 20:461-470.
86. Jepson S., Komatsu M., Haq B., Arango M.E., Huang D., Carraway C.A., Carraway K.L. Muc4/sialomucin complex, the intramembrane ErbB2 ligand, induces specific phosphorylation of ErbB2 and enhances expression of p27(kip), but does not activate mitogen-activated kinase or protein kinaseB/Akt pathways. Oncogene 2002, 21:7524-7532.
87. Workman H.C., Sweeney C., Carraway K.L. The membrane mucin Muc4 inhibits apoptosis induced by multiple insults via ErbB2-dependent and ErbB2-independent mechanisms. Cancer Res. 2009, 69:2845-2852.
88. + melanoma stem-like cells conferring resistance to taxol: an insight into the mechanisms of their resistance and response. Cancer Lett. 2014, 343:123-133.
89. + cells. Mol. Med. Rep. 2013, 7:577-584.
90. Nath S., Daneshvar K., Roy L.D., Grover P., Kidiyoor A., Mosley L., Sahraei M., Mukherjee P. MUC1 induces drug resistance in pancreatic cancer cells via upregulation of multidrug resistance genes. Oncogenesis 2013, 2:e51.
91. Sharom F.J. ABC multidrug transporters: structure, function and role in chemoresistance. Pharmacogenomics 2008, 9:105-127.
92. Greaves M., Maley C.C. Clonal evolution in cancer. Nature 2012, 481:306-313.
93. Gupta P.B., Onder T.T., Jiang G., Tao K., Kuperwasser C., Weinberg R.A., Lander E.S. Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell 2009, 138:645-659.
94. Alam M., Ahmad R., Rajabi H., Kharbanda A., Kufe D. MUC1-C oncoprotein activates ERK→C/EBPbeta signaling and induction of aldehyde dehydrogenase 1A1 in breast cancer cells. J. Biol. Chem. 2013, 288:30892-30903.
95. Stroopinsky D., Rosenblatt J., Ito K., Mills H., Yin L., Rajabi H., Vasir B., Kufe T., Luptakova K., Arnason J., Nardella C., Levine J.D., Joyce R.M., Galinsky I., Reiter Y., Stone R.M., Pandolfi P.P., Kufe D., Avigan D. MUC1 is a potential target for the treatment of acute myeloid leukemia stem cells. Cancer Res. 2013, 73:5569-5579.
96. Ponnusamy M.P., Seshacharyulu P., Vaz A., Dey P., Batra S.K. MUC4 stabilizes HER2 expression and maintains the cancer stem cell population in ovarian cancer cells. J. Ovarian Res. 2011, 4:7.
97. Jimeno A., Feldmann G., Suarez-Gauthier A., Rasheed Z., Solomon A., Zou G.M., Rubio-Viqueira B., Garcia-Garcia E., Lopez-Rios F., Matsui W., Maitra A., Hidalgo M. A direct pancreatic cancer xenograft model as a platform for cancer stem cell therapeutic development. Mol. Cancer Ther. 2009, 8:310-314.
98. Zhou J., Wang C.Y., Liu T., Wu B., Zhou F., Xiong J.X., Wu H.S., Tao J., Zhao G., Yang M., Gou S.M. Persistence of side population cells with high drug efflux capacity in pancreatic cancer. World J. Gastroenterol. 2008, 14:925-930.
99. Thiery J.P., Acloque H., Huang R.Y., Nieto M.A. Epithelial-mesenchymal transitions in development and disease. Cell 2009, 139:871-890.
100. Thiery J.P., Sleeman J.P. Complex networks orchestrate epithelial-mesenchymal transitions. Nat. Rev. Mol. Cell Biol. 2006, 7:131-142.
101. Lamouille S., Subramanyam D., Blelloch R., Derynck R. Regulation of epithelial-mesenchymal and mesenchymal-epithelial transitions by microRNAs. Curr. Opin. Cell Biol. 2013, 25:200-207.
102. Wendt M.K., Tian M., Schiemann W.P. Deconstructing the mechanisms and consequences of TGF-beta-induced EMT during cancer progression. Cell Tissue Res. 2012, 347:85-101.
103. Ahmed N., Abubaker K., Findlay J., Quinn M. Epithelial mesenchymal transition and cancer stem cell-like phenotypes facilitate chemoresistance in recurrent ovarian cancer. Curr. Cancer Drug Targets 2010, 10:268-278.
104. Lim S., Becker A., Zimmer A., Lu J., Buettner R., Kirfel J. SNAI1-mediated epithelial-mesenchymal transition confers chemoresistance and cellular plasticity by regulating genes involved in cell death and stem cell maintenance. PLoS ONE 2013, 8:e66558.
105. Voulgari A., Pintzas A. Epithelial-mesenchymal transition in cancer metastasis: mechanisms, markers and strategies to overcome drug resistance in the clinic. Biochim. Biophys. Acta 2009, 1796:75-90.
106. Yamada S., Fuchs B.C., Fujii T., Shimoyama Y., Sugimoto H., Nomoto S., Takeda S., Tanabe K.K., Kodera Y., Nakao A. Epithelial-to-mesenchymal transition predicts prognosis of pancreatic cancer. Surgery 2013, 154:946-954.
107. Comamala M., Pinard M., Theriault C., Matte I., Albert A., Boivin M., Beaudin J., Piche A., Rancourt C. Downregulation of cell surface CA125/MUC16 induces epithelial-to-mesenchymal transition and restores EGFR signalling in NIH:OVCAR3 ovarian carcinoma cells. Br. J. Cancer 2011, 104:989-999.
108. Horn G., Gaziel A., Wreschner D.H., Smorodinsky N.I., Ehrlich M. ERK and PI3K regulate different aspects of the epithelial to mesenchymal transition of mammary tumor cells induced by truncated MUC1. Exp. Cell Res. 2009, 315:1490-1504.
109. Roy L.D., Sahraei M., Subramani D.B., Besmer D., Nath S., Tinder T.L., Bajaj E., Shanmugam K., Lee Y.Y., Hwang S.I., Gendler S.J., Mukherjee P. MUC1 enhances invasiveness of pancreatic cancer cells by inducing epithelial to mesenchymal transition. Oncogene 2011, 30:1449-1459.
110. Ponnusamy M.P., Lakshmanan I., Jain M., Das S., Chakraborty S., Dey P., Batra S.K. MUC4 mucin-induced epithelial to mesenchymal transition: a novel mechanism for metastasis of human ovarian cancer cells. Oncogene 2010, 29:5741-5754.
111. Rajabi H., Alam M., Takahashi H., Kharbanda A., Guha M., Ahmad R., Kufe D. MUC1-C oncoprotein activates the ZEB1/miR-200c regulatory loop and epithelial-mesenchymal transition. Oncogene 2014, 33:1680-1689.
112. Gnemmi V., Bouillez A., Gaudelot K., Hemon B., Ringot B., Pottier N., Glowacki F., Villers A., Vindrieux D., Cauffiez C., Seuningen I.V., Bernard D., Leroy X., Aubert S., Perrais M. MUC1 drives epithelial-mesenchymal transition in renal carcinoma through Wnt/beta-catenin pathway and interaction with SNAIL promoter. Cancer Lett. 2014, 346:225-236.
113. Gao L., Liu J., Zhang B., Zhang H., Wang D., Zhang T., Liu Y., Wang C. Functional MUC4 suppress epithelial-mesenchymal transition in lung adenocarcinoma metastasis. Tumour Biol. 2014, 35:1335-1341.
114. Jonckheere N., Van Seuningen I. Comment on: Functional MUC4 suppress epithelial-mesenchymal transition in lung adenocarcinoma metastasis. Gao L, Liu J, Zhang B, Zhang H, Wang D, Zhang T, Liu Y, Wang C. Tumour Biol. 2013, in press. Tumour Biol. 2014, 35:3941-3942.
115. Fujii T., Shimada K., Anai S., Fujimoto K., Konishi N. ALKBH2, a novel AlkB homologue, contributes to human bladder cancer progression by regulating MUC1 expression. Cancer Sci. 2013, 104:321-327.
116. Lee J.W., Aminkeng F., Bhavsar A.P., Shaw K., Carleton B.C., Hayden M.R., Ross C.J. The emerging era of pharmacogenomics: current successes, future potential, and challenges. Clin. Genet. 2014, (in press). 10.1111/cge.12392.
117. Ono C., Kikkawa H., Suzuki A., Suzuki M., Yamamoto Y., Ichikawa K., Fukae M., Ieiri I. Clinical impact of genetic variants of drug transporters in different ethnic groups within and across regions. Pharmacogenomics 2013, 14:1745-1764.
118. Sai K., Saito Y. Ethnic differences in the metabolism, toxicology and efficacy of three anticancer drugs. Expert Opin. Drug Metab. Toxicol. 2011, 7:967-988.
119. Chang C.Y., Chang H.W., Chen C.M., Lin C.Y., Chen C.P., Lai C.H., Lin W.Y., Liu H.P., Sheu J.J., Tsai F.J. MUC4 gene polymorphisms associate with endometriosis development and endometriosis-related infertility. BMC Med. 2011, 9:19.
120. Saeki N., Saito A., Choi I.J., Matsuo K., Ohnami S., Totsuka H., Chiku S., Kuchiba A., Lee Y.S., Yoon K.A., Kook M.C., Park S.R., Kim Y.W., Tanaka H., Tajima K., Hirose H., Tanioka F., Matsuno Y., Sugimura H., Kato S., Nakamura T., Nishina T., Yasui W., Aoyagi K., Sasaki H., Yanagihara K., Katai H., Shimoda T., Yoshida T., Nakamura Y., Hirohashi S., Sakamoto H. A functional single nucleotide polymorphism in mucin 1, at chromosome 1q22, determines susceptibility to diffuse-type gastric cancer. Gastroenterology 2011, 140:892-902.
121. Horimasu Y., Hattori N., Ishikawa N., Kawase S., Tanaka S., Yoshioka K., Yokoyama A., Kohno N., Bonella F., Guzman J., Ohshimo S., Costabel U. Different MUC1 gene polymorphisms in German and Japanese ethnicities affect serum KL-6 levels. Respir. Med. 2012, 106:1756-1764.
122. Fowler J., Vinall L., Swallow D. Polymorphism of the human muc genes. Front. Biosci. 2001, 6:D1207-D1215.
123. Carvalho F., Seruca R., David L., Amorim A., Seixas M., Bennett E., Clausen H., Sobrinho-Simoes M. MUC1 gene polymorphism and gastric cancer-an epidemiological study. Glycoconj. J. 1997, 14:107-111.
124. Davies J.R., Wickstrom C., Thornton D.J. Gel-forming and cell-associated mucins: preparation for structural and functional studies. Methods Mol. Biol. 2012, 842:27-47.
125. Yin L., Ahmad R., Kosugi M., Kufe T., Vasir B., Avigan D., Kharbanda S., Kufe D. Survival of human multiple myeloma cells is dependent on MUC1 C-terminal transmembrane subunit oncoprotein function. Mol. Pharmacol. 2010, 78:166-174.
126. Kharbanda A., Rajabi H., Jin C., Raina D., Kufe D. Oncogenic MUC1-C promotes tamoxifen resistance in human breast cancer. Mol. Cancer Res. 2013, 11:714-723.
127. Raina D., Uchida Y., Kharbanda A., Rajabi H., Panchamoorthy G., Jin C., Kharbanda S., Scaltriti M., Baselga J., Kufe D. Targeting the MUC1-C oncoprotein downregulates HER2 activation and abrogates trastuzumab resistance in breast cancer cells. Oncogene 2014, (in press). 10.1038/onc.2013.308.
128. Uchida Y., Raina D., Kharbanda S., Kufe D. Inhibition of the MUC1-C oncoprotein is synergistic with cytotoxic agents in the treatment of breast cancer cells. Cancer Biol. Ther. 2013, 14:127-134.
129. Raina D., Kosugi M., Ahmad R., Panchamoorthy G., Rajabi H., Alam M., Shimamura T., Shapiro G.I., Supko J., Kharbanda S., Kufe D. Dependence on the MUC1-C oncoprotein in non-small cell lung cancer cells. Mol. Cancer Ther. 2011, 10:806-816.
130. Tang C.K., Apostolopoulos V. Strategies used for MUC1 immunotherapy: preclinical studies. Expert Rev. Vaccines 2008, 7:951-962.
131. Tang C.K., Katsara M., Apostolopoulos V. Strategies used for MUC1 immunotherapy: human clinical studies. Expert Rev. Vaccines 2008, 7:963-975.
132. Lakshminarayanan V., Thompson P., Wolfert M.A., Buskas T., Bradley J.M., Pathangey L.B., Madsen C.S., Cohen P.A., Gendler S.J., Boons G.J. Immune recognition of tumor-associated mucin MUC1 is achieved by a fully synthetic aberrantly glycosylated MUC1 tripartite vaccine. Proc. Natl. Acad. Sci. U. S. A. 2011, 109:261-266.
133. Beatson R.E., Taylor-Papadimitriou J., Burchell J.M. MUC1 immunotherapy. Immunotherapy 2010, 2:305-327.
134. Liu N., Zhou C., Zhao J., Chen Y. Reversal of paclitaxel resistance in epithelial ovarian carcinoma cells by a MUC1 aptamer-let-7i chimera. Cancer Investig. 2012, 30:577-582.
135. Dai F., Zhang Y., Zhu X., Shan N., Chen Y. The anti-chemoresistant effect and mechanism of MUC1 aptamer-miR-29b chimera in ovarian cancer. Gynecol. Oncol. 2013, 131:451-459.
136. Duffy M.J. Tumor markers in clinical practice: a review focusing on common solid cancers. Med. Princ. Pract. 2013, 22:4-11.
137. de Campos-Lobato L.F., Dietz D.W., Stocchi L., Vogel J.D., Lavery I.C., Goldblum J.R., Skacel M., Pelley R.J., Kalady M.F. Clinical implications of acellular mucin pools in resected rectal cancer with pathological complete response to neoadjuvant chemoradiation. Colorectal Dis. 2012, 14:62-67.
138. Smith K.D., Tan D., Das P., Chang G.J., Kattepogu K., Feig B.W., Skibber J.M., Rodriguez-Bigas M.A. Clinical significance of acellular mucin in rectal adenocarcinoma patients with a pathologic complete response to preoperative chemoradiation. Ann. Surg. 2010, 251:261-264.
139. Shia J., McManus M., Guillem J.G., Leibold T., Zhou Q., Tang L.H., Riedel E.R., Weiser M.R., Paty P.B., Temple L.K., Nash G., Kolosov K., Minsky B.D., Wong W.D., Klimstra D.S. Significance of acellular mucin pools in rectal carcinoma after neoadjuvant chemoradiotherapy. Am. J. Surg. Pathol. 2011, 35:127-134.
140. Budiu R.A., Mantia-Smaldone G., Elishaev E., Chu T., Thaller J., McCabe K., Lenzner D., Edwards R.P., Vlad A.M. Soluble MUC1 and serum MUC1-specific antibodies are potential prognostic biomarkers for platinum-resistant ovarian cancer. Cancer Immunol. Immunother. 2011, 60:975-984.
141. Aubert S., Van Seuningen I., Leroy X. Mucins in the uro-genital tract. Potential for therapeutic approaches using mucins. The Epithelial Mucins: Structure/Function. Roles in Cancer and Inflammatory Diseases 2008, 249-272. Research Signpost, Kerala, India. I. Van Seuningen (Ed.).
142. Di Gioia D., Heinemann V., Nagel D., Untch M., Kahlert S., Bauerfeind I., Koehnke T., Stieber P. Kinetics of CEA and CA15-3 correlate with treatment response in patients undergoing chemotherapy for metastatic breast cancer (MBC). Tumour Biol. 2011, 32:777-785.
143. Cheng J.P., Yan Y., Wang X.Y., Lu Y.L., Yuan Y.H., Jia J., Ren J. MUC1-positive circulating tumor cells and MUC1 protein predict chemotherapeutic efficacy in the treatment of metastatic breast cancer. Chin. J. Cancer 2011, 30:54-61.